Investment Thesis
Arcadia Biosciences faces imminent liquidity crisis with $259K cash reserves against $4.7M annual operating burn, providing only 1.3 weeks of operational runway. Despite impressive 2098% revenue growth, the company operates at -48% net margin and -51.5% operating margin, losing $2.3M on $4.9M revenue, indicating a fundamentally unsustainable business model.
Strengths
- Exceptional 2098% year-over-year revenue growth demonstrates significant market traction or business expansion from prior period
- Zero long-term debt eliminates financial leverage risk and restructuring concerns
- Current ratio of 3.09x and quick ratio of 2.50x indicate asset-to-liability positioning superior to cash position alone
Risks
- Critical liquidity crisis: $259K cash insufficient for $4.7M annual operating burn (approximately 13 days of runway)
- Operating model fundamentally broken with negative operating cash flow of $4.7M exceeding revenue generation of $4.9M
- Severe unprofitability with -48.1% net margin, -51.5% operating margin, and negative returns on equity (-56.5%) and assets (-35.7%)
Key Metrics to Watch
- Monthly cash burn rate and days of liquid capital remaining - immediate survival metric
- Operating cash flow trajectory - must achieve positive OCF within weeks to avoid insolvency
- Revenue growth sustainability and gross margin - assess whether growth is profitable or accelerating cash depletion
Financial Metrics
Revenue
4.9M
Net Income
-2.3M
EPS (Diluted)
$-1.71
Free Cash Flow
-4.7M
Total Assets
6.5M
Cash
259.0K
Profitability Ratios
Gross Margin
N/A
Operating Margin
-51.5%
Net Margin
-48.1%
ROE
-56.5%
ROA
-35.7%
FCF Margin
-97.6%
Balance Sheet & Liquidity
Current Ratio
3.09x
Quick Ratio
2.50x
Debt/Equity
0.00x
Debt/Assets
36.8%
Interest Coverage
-2,500.00x
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-09T14:50:29.019148 |
Data as of: 2025-12-31 |
Powered by Claude AI